Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Pneumonias due to Pneumocystis carinii (
PCP
) commonly occur in immunocompromised hosts. Although a treatable infection, it is associated with high mortality. A case of
PCP
presenting in an untreated case of
systemic lupus erythematosus
is reported, in view of the rarity of this association.
...
PMID:Pneumocystis carinii pneumonia in a patient with active untreated systemic lupus erythematosus. 1152 37
Pneumocystis carini (
PCP
) has been recognized as a cause of pneumonia in immuocompromised patients, most notably in AIDS patients, but also in those receiving immunosuppressive therapy for a variety of other conditions, including malignancy, having an organ transplant, connective tissue diseases, and vasculitic syndromes. In non-HIV
PCP
patients, presentations may be more dramatic than in HIV-related
PCP
and the mortality may be higher, thus emphasizing the need to identify and provide prophylaxis for those at highest risk for
PCP
. The incidence of
PCP
varies in different rheumatic disorders, with the highest rated noted in Wegener's granulomatosis and the lowest noted in rheumatoid arthritis. Prophylactic regimens should be used in patients with Wegener's granulomatosis taking cyclophosphamide and daily corticosteroids and in other rheumatic disease patients who are treated with this regimen, such as in PAN, microscopic polyarteritis, or severe
systemic lupus erythematosus
. Prophylaxis should be strongly considered in patients taking prolonged, high doses of daily corticosteroids (>40mg/day for > 3 months) with a second immunosuppressive agent other than cyclophosphamide, such as methotrexate, for example, as in PM/DM and in alternative regimens for Wegener's granulomatosis. Emerging data suggest the utility of CD4 counts as a method to distinguish those at highest risk for
PCP
to selectively apply prophylactic therapy. TMP-SMX is the usual first choice for prohpylaxis.
...
PMID:Pneumocystis carinii pneumonia prophylaxis in patients with rheumatic diseases undergoing immunosuppressive therapy: prealence and associated features. 1907 57